Age-related decline in anti-HBV antibodies in vaccinated kidney transplant recipients.
aging
kidney transplantation
vaccine
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
14
05
2023
accepted:
08
06
2023
medline:
15
8
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
ppublish
Résumé
Hepatitis B virus (HBV) vaccination is indicated for all end stage kidney disease patients, including all solid organ transplant candidates. Maintenance of adequate immunity is especially important for immunosuppressed solid organ recipients who are at increased risk for donor or community acquired HBV. The impact of age and immunosuppression on long-term maintenance of HBV immunity postvaccination has not been fully investigated. We performed a single-center retrospective study of 96 kidney transplant recipients, transplanted between July 2012 and December 2020, who had Hepatitis B surface antibody (HBsAb) levels measured pretransplantation and 1-year posttransplantation. We compared the change in HBsAb levels stratified by patient's age (<45, 45-60, and >60) and by whether or not the patient received lymphocyte depleting induction therapy. Our results demonstrate that HBsAb IgG levels vary by age group, decreased significantly at 1-year posttransplant (p < .0001) and were significantly lower in the older cohort (p = .03). Among recipients who received rabbit anti-thymocyte globulin induction (rATG), the log HbsAb levels were significantly lower in the older age group (2.15 in age <45, 1.75 in age 45-60 and 1.47 in age >60, p = .01). Age group (p = .004), recipient HBcAb status (p = .002), and rATG (p = .048) were independently associated with >20% reduction in log HBsAb levels posttransplant. Significant declines in HBsAb levels occur postkidney transplantation, especially in older individuals, thus placing exposed older kidney transplant recipients at greater risk of HBV infection and associated complications.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatitis B virus (HBV) vaccination is indicated for all end stage kidney disease patients, including all solid organ transplant candidates. Maintenance of adequate immunity is especially important for immunosuppressed solid organ recipients who are at increased risk for donor or community acquired HBV. The impact of age and immunosuppression on long-term maintenance of HBV immunity postvaccination has not been fully investigated.
METHODS
METHODS
We performed a single-center retrospective study of 96 kidney transplant recipients, transplanted between July 2012 and December 2020, who had Hepatitis B surface antibody (HBsAb) levels measured pretransplantation and 1-year posttransplantation. We compared the change in HBsAb levels stratified by patient's age (<45, 45-60, and >60) and by whether or not the patient received lymphocyte depleting induction therapy.
RESULTS
RESULTS
Our results demonstrate that HBsAb IgG levels vary by age group, decreased significantly at 1-year posttransplant (p < .0001) and were significantly lower in the older cohort (p = .03). Among recipients who received rabbit anti-thymocyte globulin induction (rATG), the log HbsAb levels were significantly lower in the older age group (2.15 in age <45, 1.75 in age 45-60 and 1.47 in age >60, p = .01). Age group (p = .004), recipient HBcAb status (p = .002), and rATG (p = .048) were independently associated with >20% reduction in log HBsAb levels posttransplant.
CONCLUSION
CONCLUSIONS
Significant declines in HBsAb levels occur postkidney transplantation, especially in older individuals, thus placing exposed older kidney transplant recipients at greater risk of HBV infection and associated complications.
Substances chimiques
Hepatitis B Antibodies
0
Hepatitis B Surface Antigens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14090Informations de copyright
© 2023 Wiley Periodicals LLC. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Références
NIH/NIDDK. Kidney disease in the United States. Centers for Disease Control and Prevention; US Department of Health and Human Services; 2021. https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease
Kanaan N, Kabamba B, Marechal C, et al. Significant rate of hepatitis B reactivation following kidney transplantation in patients with resolved infection. J Clin Virol. 2012;55:233-238.
CDC. Center for Disease Control and Prevention - viral hepatitis. US Department of Health and Human Services; 2020. https://wwwcdcgov/hepatitis/hbv/hbvfaqhtm#ref02
Roberts H, Ly KN, Yin S, Hughes E, Teshale E, Jiles R. Prevalence of HBV infection, vaccine-induced immunity, and susceptibility among at-risk populations: US households, 2013-2018. Hepatology. 2021;74:2353-5365.
Saco TV, Strauss AT, Ledford DK. Hepatitis B vaccine nonresponders: possible mechanisms and solutions. Ann Allergy Asthma Immunol. 2018;121:320-327.
Dugan HL, Henry C, Wilson PC. Aging and influenza vaccine-induced immunity. Cell Immunol. 2020;348:103998.
Haralambieva IH, Painter SD, Kennedy RB, et al. The impact of immunosenescence on humoral immune response variation after influenza A/H1N1 vaccination in older subjects. PLoS One. 2015;10:e0122282.
Lentine KL, Smith JM, Miller JM, et al. OPTN/SRTR 2021 annual data report: kidney. Am J Transplant. 2023;23:S21-S120.
Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population-results of a 10-year study. J Infect Dis. 1997;175:674-677.
Chancharoenthana W, Leelahavanichkul A, Udomkarnjananun S, et al. Durability of antibody response against the hepatitis B virus in kidney transplant recipients: a proposed immunization guideline from a 3-year follow-up clinical study. Open Forum Infect Dis. 2019;6:ofy342.
Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2016 annual data report: kidney. Am J Transplant. 2018;18(Suppl 1):18-113.
Moal V, Motte A, Vacher-Coponat H, Tamalet C, Berland Y, Colson P. Considerable decrease in antibodies against hepatitis B surface antigen following kidney transplantation. J Clin Virol. 2015;68:32-36.
Agency UHS. Hepatitis B: the green book, chapter 18. Agency UHS; 2013. https://www.gov.uk/government/publications/hepatitis-b-the-green-book-chapter-18
Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep. 2018;67:1-31.
Kakisaka K, Sakai A, Yoshida Y, et al. Hepatitis B surface antibody titers at one and two years after hepatitis B virus vaccination in healthy young Japanese adults. Intern Med. 2019;58:2349-2355.
Krenzien F, ElKhal A, Quante M, et al. A rationale for age-adapted immunosuppression in organ transplantation. Transplantation. 2015;99:2258-2268.
Crepin T, Legendre M, Carron C, et al. Uraemia-induced immune senescence and clinical outcomes in chronic kidney disease patients. Nephrol Dial Transplant. 2020;35:624-632.
George RP, Mehta AK, Perez SD, et al. Premature T cell senescence in pediatric CKD. J Am Soc Nephrol. 2017;28:359-367.
Schaier M, Gottschalk C, Uhlmann L, et al. Immunosuppressive therapy influences the accelerated age-dependent T-helper cell differentiation in systemic lupus erythematosus remission patients. Arthritis Res Ther. 2018;20:278.
Leonhard J, Schaier M, Kalble F, Eckstein V, Zeier M, Steinborn A. Chronic kidney failure provokes the enrichment of terminally differentiated CD8(+) T cells, impairing cytotoxic mechanisms after kidney transplantation. Front Immunol. 2022;13:752570.
Higdon LE, Gustafson CE, Ji X, et al. Association of premature immune aging and cytomegalovirus after solid organ transplant. Front Immunol. 2021;12:661551.
Lorenz EC, Hickson LJ, Khairallah P, Najafi B, Kennedy CC. Cellular senescence and frailty in transplantation. Curr Transplant Rep. 2023;10:51-59.
Kinnunen S, Karhapaa P, Juutilainen A, Finne P, Helantera I. Secular trends in infection-related mortality after kidney transplantation. Clin J Am Soc Nephrol. 2018;13:755-762.
Agrawal A, Ison MG, Danziger-Isakov L. Long-term infectious complications of kidney transplantation. Clin J Am Soc Nephrol. 2022;17:286-295.
Schneider S, Carlson A, Sirandas B, Clark B, Truax C. Serologic evaluation of vaccine preventable infections and vaccination rates in kidney transplant candidates. Transpl Infect Dis. 2022;24:e13973.
Bardosh K, de Figueiredo A, Gur-Arie R, et al. The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good. BMJ Glob Health. 2022;7:e008684.
Soni R, Horowitz B, Unruh M. Immunization in end-stage renal disease: opportunity to improve outcomes. Semin Dial. 2013;26:416-426.
Krueger KM, Ison MG, Ghossein C. Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation. Am J Kidney Dis. 2020;75:417-425.
Siciliani L, Wild C, McKee M, et al. Strengthening vaccination programmes and health systems in the European Union: a framework for action. Health Policy. 2020;124:511-518.
Huprikar S, Danziger-Isakov L, Ahn J, et al. Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. Am J Transplant. 2015;15:1162-1172.